drugset / Trial / NCT05223582
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Timeline
- Start
- 2021-05-01
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | — |
| Subject | Fluzoparib | Small molecule | 150 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |